▟ Vinebot intrinsic value, daily

← back

FTV Fortive

industrial · valued with opus medium conviction · deep-dived 2026-11-06

SELL
Intrinsic value$31.63
Price (at call)$65.42
Margin of safety -51.7%
vs market (rating basis) -20.3%

Asset-light post-spin Fortive throws off cash; fair value near market, little margin of safety.

The story

Post-Ralliant-spin Fortive is a leaner portfolio of software-enabled industrial tools (Fluke, Tektronix-adjacent instrumentation, Gordian/Accruent software, ASP sterilization). It has sticky installed bases, a high-margin recurring software mix and a strong Fortive Business System culture. As a mature, cash-generative compounder, it grows low-to-mid single digits organically, boosted by bolt-on M&A and heavy buybacks.

TTM revenue (+5.8%) and operating margin (19.8%, up from 17.4%) confirm the post-spin margin story, so I nudge target margin to 24%. Sales-to-capital moves materially from 0.9 to 2.0: the 0.46 reported figure is inflated by goodwill from past acquisitions, while capex ($0.07B against $0.45B D&A) shows organic reinvestment needs are light. My prior value (27.66) sat more than 50% below a market price backed by a roughly 4.5% FCF-to-EV yield, which signaled that this driver was too punitive.

Value drivers

Revenue growth (Y1)5.5%
Terminal growth3.0%
Forecast horizon7y
Target operating margin24.0%
Years to target margin6
Sales-to-capital2.00
Beta1.05
Failure probability2.0%
Cost of capital (WACC)9.1%
Terminal WACC8.9%

Valuation bridge

PV of explicit FCFF4.63B
PV of terminal value7.81B
Equity value9.41B
÷ shares → per share$31.63

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 4.64B 5.5% 20.5% 839.93M 120.90M 719.04M 658.89M
2 4.87B 5.1% 21.2% 913.04M 117.88M 795.16M 667.70M
3 5.10B 4.7% 21.9% 987.49M 113.72M 873.77M 672.33M
4 5.32B 4.2% 22.6% 1.06B 108.40M 954.24M 672.83M
5 5.52B 3.8% 23.3% 1.14B 101.93M 1.04B 669.32M
6 5.71B 3.4% 24.0% 1.21B 94.33M 1.12B 661.94M
7 5.88B 3.0% 24.0% 1.25B 85.66M 1.16B 631.01M

Key risks

  • Industrial/capex cycle softness hitting Fluke and instrumentation volumes
  • Value-destructive or overpriced M&A as growth substitute
  • Healthcare/software segment growth stalling, eroding the multiple premium

Catalysts

  • Continued margin expansion and buyback-driven EPS growth post-spin
  • Recovery in industrial demand lifting organic growth toward 4-5%

History

DatePriceIntrinsicMoSRating
2026-11-06$65.42 $31.63 -51.7% SELL
2026-07-31$58.48 $27.66 -52.7% HOLD
2026-06-23$60.34 $28.37 -53.0% HOLD